Cerus Co. (NASDAQ:CERS) SVP Carol Moore sold 10,886 shares of Cerus stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.01, for a total value of $65,424.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of CERS traded down $0.12 during midday trading on Thursday, hitting $6.16. The company had a trading volume of 35,697 shares, compared to its average volume of 842,462. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.53 and a current ratio of 2.79. The stock has a market capitalization of $877.87 million, a PE ratio of -14.01 and a beta of 1.44. Cerus Co. has a 1 year low of $4.70 and a 1 year high of $8.05.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $16.50 million during the quarter, compared to analysts’ expectations of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) EPS. Analysts predict that Cerus Co. will post -0.42 EPS for the current year.

Several equities analysts have weighed in on the company. Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Monday, March 4th. BidaskClub downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. ValuEngine raised Cerus from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 target price on shares of Cerus in a research report on Tuesday, December 18th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $8.50.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Cerus by 1.2% in the 4th quarter. BlackRock Inc. now owns 10,794,407 shares of the biotechnology company’s stock valued at $54,727,000 after buying an additional 123,643 shares during the period. Vanguard Group Inc lifted its stake in Cerus by 2.4% during the third quarter. Vanguard Group Inc now owns 6,626,832 shares of the biotechnology company’s stock worth $47,779,000 after purchasing an additional 154,112 shares during the last quarter. Vanguard Group Inc. lifted its stake in Cerus by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,626,832 shares of the biotechnology company’s stock worth $47,779,000 after purchasing an additional 154,112 shares during the last quarter. Elk Creek Partners LLC lifted its stake in Cerus by 11.4% during the fourth quarter. Elk Creek Partners LLC now owns 5,755,232 shares of the biotechnology company’s stock worth $29,179,000 after purchasing an additional 586,820 shares during the last quarter. Finally, Norges Bank purchased a new stake in Cerus during the fourth quarter worth approximately $12,997,000. Institutional investors and hedge funds own 65.15% of the company’s stock.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/cerus-co-cers-svp-carol-moore-sells-10886-shares/2890400.html.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Recommended Story: Stochastic Momentum Index (SMI)

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.